Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 691 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL July 29, 2021 Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With... May 30, 2022 Rise in Brain Metastases Detected in Patients with Stage IV NSCLC... March 24, 2021 Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H... May 3, 2024 Load more HOT NEWS Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus... PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients... Significant Activity, Clinically Meaningful Functional and Symptomatic Improvements Observed in Patients... Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast...
